FDA Approves Velosulin BR For Diabetes Treatment
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Velosulin BR For Diabetes Treatment

PRINCETON, NJ -- July 20, 1999 -- The United States Food and Drug Administration has approved Novo Nordisk A/S’ Velosulin(R)BR (human buffered regular insulin [rDNA origin] injection) for people with diabetes.

It is indicated for use in external insulin infusion pumps and with U-100 insulin syringes.

Novo Nordisk will begin marketing recombinant Velosulin BR later this year and it will eventually replace the semi-synthetic version of Velosulin BR that is currently available. The active drug in the recombinant form of Velosulin BR is structurally identical to the insulin produced by the pancreas in the human body. The formulation is not significantly different from semi- synthetic Velosulin BR, which has been available for pump use in the U.S. since 1986. In the U.S., approximately five percent of people with type I diabetes use an insulin pump to help manage their diabetes.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities